4-12-24 : My comments at the FDA Advisory meeting on the irresponsible use of MRD for AA

4-12-24 : My comments at the FDA Advisory meeting on the irresponsible use of MRD for AA

April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)See more

April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

FAQ 004614 | For a line support, I get an error message saying that the line is not assigned to ...See more

FAQ 004614 | For a line support, I get an error message saying that the line is not assigned to ...

Depth of molecular response in patients with TP53m MDS & AML treated with magrolimab and azacitidineSee more

Depth of molecular response in patients with TP53m MDS & AML treated with magrolimab and azacitidine

September 13, 2023 Meeting of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC)See more

September 13, 2023 Meeting of the Cardiovascular and Renal Drugs Advisory Committee (CRDAC)

The CAR T-cell strategy vs bispecific antibodiesSee more

The CAR T-cell strategy vs bispecific antibodies

March 5, 2024 Meeting of the Medical Imaging Drugs Advisory Committee (MIDAC)See more

March 5, 2024 Meeting of the Medical Imaging Drugs Advisory Committee (MIDAC)

FAQ 002289 | When starting the program, I get warning No. 10312 "Program authorization failed".See more

FAQ 002289 | When starting the program, I get warning No. 10312 'Program authorization failed'.

Advisory Committee Meeting on 4 12 24See more

Advisory Committee Meeting on 4 12 24

RIC vs MAC in MRD-positive & MRD-negative patients with AMLSee more

RIC vs MAC in MRD-positive & MRD-negative patients with AML

BiTEs in myeloma – when and who?See more

BiTEs in myeloma – when and who?

Where does MRD belong as a tool in myeloma?See more

Where does MRD belong as a tool in myeloma?

MRD assessment: NGS vs. flow cytometrySee more

MRD assessment: NGS vs. flow cytometry

Pre-transplant MRD status by NGS as a prognostic tool for AML and MDSSee more

Pre-transplant MRD status by NGS as a prognostic tool for AML and MDS

An update on MRD assessment and novel techniques used in the treatment of hematological malignanciesSee more

An update on MRD assessment and novel techniques used in the treatment of hematological malignancies

If a myeloma patient has MRD-negative status, does that mean that patient is cured?See more

If a myeloma patient has MRD-negative status, does that mean that patient is cured?

Improving the use of MRD for the prognosis and treatment of ALLSee more

Improving the use of MRD for the prognosis and treatment of ALL

Steve, a multiple myeloma patient, and the value of MRD testingSee more

Steve, a multiple myeloma patient, and the value of MRD testing

ESH 3rd How to Diagnose and Treat Multiple Myeloma: virtual tour of the E-Conference platformSee more

ESH 3rd How to Diagnose and Treat Multiple Myeloma: virtual tour of the E-Conference platform

Events